

Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC

Leuven, BELGIË – 19 februari 2026 – 18u00 CET [Oxurion NV](#) (Euronext Brussel: OXUR), een bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving¹, de volgende transparantiekennisgeving heeft ontvangen:

Oxurion ontving een transparantiekennisgeving op 18 februari 2026 van Atlas Special Opportunities II LLC waaruit blijkt dat het op 16 februari 2026 3.458.157 aandelen van de toen uitstaande 70.098.394 aandelen bezat en dus onder de drempel (5%) kwam door de verkoop van stemrechtverlenende effecten.

Over Oxurion

Oxurion NV (Euronext Brussel: OXUR) is een bedrijf dat zich specialiseert in het verwerven van meerderheidsbelangen in veelbelovende Europese farmaceutische onderaannemers. Oxurion heeft de ambitie om een geïntegreerde groep van onderaannemers op te bouwen die de gezondheidszorgsector bedient. Het hoofdkantoor van de groep is gevestigd in Leuven, België. Meer informatie is beschikbaar op www.oxurion.com.

Belangrijke informatie over toekomstgerichte verklaringen

Bepaalde verklaringen in dit persbericht kunnen als "toekomstgericht" worden beschouwd. Dergelijke toekomstgerichte verklaringen zijn gebaseerd op de huidige verwachtingen en brengen dienovereenkomstig verschillende risico's en onzekerheden met zich mee en worden ze beïnvloed. Het bedrijf kan daarom geen enkele garantie geven dat dergelijke toekomstgerichte verklaringen zullen materialiseren en aanvaardt geen enkele verplichting om een toekomstgerichte verklaring bij te werken of te herzien, hetzij als gevolg van nieuwe informatie, toekomstige gebeurtenissen of enige andere reden. Aanvullende informatie over risico's en onzekerheden die van invloed zijn op het bedrijf en andere factoren die ertoe kunnen leiden dat de werkelijke resultaten wezenlijk verschillen van een toekomstgerichte verklaring, is opgenomen in het jaarverslag van het bedrijf. Dit persbericht vormt geen aanbod of uitnodiging voor de verkoop of aankoop van effecten of activa van Oxurion in enig rechtsgebied. Er mogen geen effecten van Oxurion worden aangeboden of verkocht in de Verenigde Staten zonder registratie onder de U.S. Securities Act van 1933, zoals gewijzigd, of in overeenstemming met een vrijstelling daarvan, en in overeenstemming met toepasselijke Amerikaanse effectenwetten.

Aanvullende waarschuwing

De geplande investering in digitale activa (zoals Bitcoin en Ethereum) stelt de vennootschap bloot aan specifieke risico's die verband houden met volatiliteit, onduidelijke regelgeving en cybeveiligheid. Deze factoren kunnen een aanzienlijke impact hebben op het verwachte rendement van de investeringen.

Voor meer informatie kunt u contact opnemen met:

<p>Oxurion NV Pascal Ghoson, Chief Executive Officer Pascal.ghoson@oxurion.com</p>

1. Art 14, eerste alinea, van de Wet van 2 mei 2007 betreffende de openbaarmaking van belangrijke deelnemingen.

ANNEX 1

1) Status of the notification

Final

2) Issuer

Name: OXURION
 Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

i Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

16/02/2026 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

5

i If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

70,098,394

i Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification # of voting rights	After the transaction			
		# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	6,337,343	3,458,157	0	4.93%	0.00%
TOTAL		3,458,157	0	4.93%	0.00%

i Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments							After the transaction	
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement		
							+	
TOTAL				0	0.00%			

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	3,458,157	4.93%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.


12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 20 January 2025 (with settlement date on 22 January 2026), Atlas Special Opportunities II LLC sold 1,934,335 shares in Oxurion NV, as a result of which its shareholding decreased to 6,337,343 shares (= 9.040%, denominator = 70,098,394)
 On 21 January 2026 (with settlement date on 23 January 2026), Atlas Special Opportunities II LLC sold 82,437 shares in Oxurion NV, as a result of which its shareholding decreased to 6,254,906 shares (= 8.923%, denominator = 70,098,394)
 On 22 January 2026 (with settlement date on 26 January 2026), Atlas Special Opportunities II LLC sold 1 share in Oxurion NV, as a result of which its shareholding decreased to 6,254,905 shares (= 8.923%, denominator = 70,098,394)
 On 23 January 2026 (with settlement date on 27 January 2026), Atlas Special Opportunities II LLC sold 5,000 shares in Oxurion NV, as a result of which its shareholding decreased to 6,249,905 shares (= 8.916%, denominator = 70,098,394)
 On 27 January 2026 (with settlement date on 29 January 2026), Atlas Special Opportunities II LLC sold 5,001 shares in Oxurion NV, as a result of which its shareholding decreased to 6,244,904 shares (= 8.909%, denominator = 70,098,394)
 On 4 February 2026 (with settlement date on 6 February 2026), Atlas Special Opportunities II LLC sold 137,122 shares in Oxurion NV, as a result of which its shareholding decreased to 6,107,782 shares (= 8.713%, denominator = 70,098,394)
 On 5 February 2026 (with settlement date on 9 February 2026), Atlas Special Opportunities II LLC sold 66,984 shares in Oxurion NV, as a result of which its shareholding decreased to 6,040,798 shares (= 8.618%, denominator = 70,098,394)
 On 6 February 2026 (with settlement date on 10 February 2026), Atlas Special Opportunities II LLC sold 255,424 shares in Oxurion NV, as a result of which its shareholding decreased to 5,785,374 shares (= 8.253%, denominator = 70,098,394)
 On 9 February 2026 (with settlement date on 11 February 2026), Atlas Special Opportunities II LLC sold 290,725 shares in Oxurion NV, as a result of which its shareholding decreased to 5,494,649 shares (= 7.838%, denominator = 70,098,394)
 On 10 February 2026 (with settlement date on 12 February 2026), Atlas Special Opportunities II LLC sold 1,608,179 shares in Oxurion NV, as a result of which its shareholding decreased to 3,886,470 shares (= 5.544%, denominator = 70,098,394)
 On 11 February 2026 (with settlement date on 13 February 2026), Atlas Special Opportunities II LLC sold 106,545 shares in Oxurion NV, as a result of which its shareholding decreased to 3,779,925 shares (= 5.392%, denominator = 70,098,394)
 On 12 February 2026 (with settlement date on 16 February 2026), Atlas Special Opportunities II LLC sold 321,768 shares in Oxurion NV, as a result of which its shareholding decreased to 3,458,157 shares (= 4.933%, denominator = 70,098,394)

Done at
 On (DD/MM/YYYY)
 Name & capacity

Signed by:
 Signature 
 9A8C4789B05442E...

For security reasons, the unsigned form in **xlsx** format should

be transmitted to trp_fin@fsma.be. You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.